A resident of Vero Beach, Florida, Quinton Oswald is an accomplished business executive with a proven track record of revenue generation and team leadership. Over the past 25 years, he has held various general management roles in Europe, South Africa, and the United States. For three years, Vero Beach resident Quinton Oswald served as CEO of Notal Vision, an early-stage company focused on developing a patient-based diagnostic and monitoring platform for early identification of the switch from dry to wet AMD.

Dry AMD, or dry age-related macular degeneration, is an eye disorder that happens when a light-sensitive tissue called the macular atrophies becomes thinner due to aging. The condition occurs in three different stages, which are early stage, intermediate stage, and late stage.

Early dry AMD results in no symptoms. Intermediate dry AMD sometimes causes difficulty seeing in low light and mild blurriness in central vision. Late dry AMD, the most severe, causes significant blurriness of central vision, affecting the ability to read texts, see straight lines, or even recognize faces. Dry AMD solely affects central vision and does not cause total blindness.

Most people develop early AMD in their 50s without knowledge of the condition due to the absence of symptoms. When a person notices symptoms of dry AMD alone, the condition will have already progressed to the intermediate or late stage. Dry AMD is irreversible, but treatment can delay the progression of the disease. To improve their chances of detecting and managing the condition at an early stage, people over the age of 50 should check for AMD with their eye doctors regularly.

Either or both eyes can show symptoms of AMD, depending on the stage of macular degeneration in each eye. Sometimes, the condition affects only one eye, and treatment can help delay progression in the affected eye while reducing the risk of symptomatic macular degeneration in the other eye.